BACKGROUND - We investigated whether age influences the predictiveness of genetic risk score (GRS) for prostate cancer (PCa) in a Chinese hospital-based biopsy cohort.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
METHODS - We included consecutive patients who underwent prostate biopsies in two tertiary centers between 2012 and 2014. GRS was calculated using 24 PCa-associated genetic variants and its predictiveness was assessed by area under curve (AUC).
RESULTS - Of 1120 men tested, 724 with prostate-specific antigen (PSA) < 20 ng/ml were selected for further analysis. Patients were divided into 3 groups by age cutoffs at 60 and 70 years. GRS significantly predicted PCa for all patients (AUC: 0.561; 95% CI: 0.514-0.609) and was an independent predictor in multivariate analysis for the 60-70 year-olds (AUC: 0.612, 95% CI: 0.541-0.684), but not for patients aged < 60 years or ≥70 years. For PCa with Gleason score ≥7, GRS discriminative ability was 0.582 (95% CI=0.527-0.637) for all patients, and 0.647 (95% CI: 0.541-0.684) for the 60-70 year-old group.
CONCLUSION - GRS significantly increased clinical prediction of PCa and high-grade disease in Chinese men aged 60-70 years, which implies that men in this age group would benefit most from genetic testing.
Oncotarget. 2015 May 15. [Epub ahead of print]
Zhu Y1,2, Han CT1,2, Chen HT3,4,5, Liu F3,4,5, Zhang GM1,2, Yang WY1,2, Xu JF3,4,5,6, Ye DW1,2.
1 Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
2 Department of Oncology, Shanghai Medical Colleague, Fudan University, Shanghai, China.
3 Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China.
4 State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China.
5 Center for Genetic Epidemiology, School of Life Sciences, Fudan University, Shanghai, China.
6 Center for Cancer Genomics, Wake Forest School of Medicine, Winston-Salem, NC, USA.